Factor VII Antibody (CaFVII-22): sc-101369

Factor VII Antibody (CaFVII-22) is a mouse monoclonal IgG1 kappa light chain antibody that detects Factor VII protein of human origin by western blotting (WB), immunofluorescence (IF), immunoprecipitation with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-Factor VII antibody (CaFVII-22) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Factor VII, also known as serum prothrombin conversion accelerator, proconvertin, or coagulation factor 7, plays a crucial role in the coagulation cascade, which is essential for hemostasis following tissue injury. This 406 amino acid protein is a vitamin K-dependent serine protease synthesized in the liver and circulates as an inactive precursor. Upon tissue injury, Factor VII is activated through proteolytic cleavage by factors such as Factor IX A, Factor X A, Factor XII A, or thrombin, resulting in the formation of Factor VII A, an active serine protease that consists of a heavy chain linked by disulfide bonds to a light chain, which contains two epidermal growth factor-like domains. The activation of Factor VII is vital as Factor VII initiates the extrinsic pathway of coagulation, leading to the generation of thrombin and the subsequent formation of fibrin clots, thereby promoting platelet aggregation and preventing excessive bleeding. Mutations in the F7 gene can lead to Factor VII deficiencies, which are often asymptomatic or present with mild bleeding tendencies, underscoring the importance of Factor VII in maintaining hemostatic balance.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Factor VII Antibody (CaFVII-22) References:

1. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1.  |  Chambers, RC., et al. 2000. J Biol Chem. 275: 35584-91. PMID: 10952976
2. Molecular analysis of the genotype-phenotype relationship in factor VII deficiency.  |  Millar, DS., et al. 2000. Hum Genet. 107: 327-42. PMID: 11129332
3. Factor VII deficiency and the FVII mutation database.  |  McVey, JH., et al. 2001. Hum Mutat. 17: 3-17. PMID: 11139238
4. The coagulation cascade: initiation, maintenance, and regulation.  |  Davie, EW., et al. 1991. Biochemistry. 30: 10363-70. PMID: 1931959
5. Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo.  |  Sidelmann, JJ., et al. 2011. Thromb Res. 128: e67-72. PMID: 21737124
6. Basic mechanisms in blood coagulation.  |  Davie, EW. and Fujikawa, K. 1975. Annu Rev Biochem. 44: 799-829. PMID: 237463
7. Evaluation of factor VII antigen in factor VII congenital deficiencies with a new ELISA assay.  |  Tirindelli, MC., et al. 1987. Am J Hematol. 26: 313-21. PMID: 2961255
8. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation.  |  O'Hara, PJ., et al. 1987. Proc Natl Acad Sci U S A. 84: 5158-62. PMID: 3037537
9. Characterization of a cDNA coding for human factor VII.  |  Hagen, FS., et al. 1986. Proc Natl Acad Sci U S A. 83: 2412-6. PMID: 3486420
10. Characterization and comparison of immune-depleted and hereditary factor-VII-deficient plasmas as substrate plasmas for factor VII assays.  |  Brandt, JT., et al. 1986. Am J Clin Pathol. 85: 583-9. PMID: 3518398
11. The coagulation factor VII in pregnancy.  |  Dalaker, K. and Prydz, H. 1984. Br J Haematol. 56: 233-41. PMID: 6607066
12. Factor VII and activated factor VII content of prothrombin complex concentrates.  |  Fiedler, H. 1998. Vox Sang. 75: 72-3. PMID: 9779562

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Factor VII Antibody (CaFVII-22) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-Factor VII Antibody (CaFVII-22) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Factor VII Antibody (CaFVII-22) Specifications

Alternate Product Name: Factor VII

Product Clone Name: CaFVII-22

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Factor VII

Epitope Species: human

Product Reactivity/Detection: the Gla-domain of Factor VII

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for Factor VII Antibody (CaFVII-22): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin